Leisureworld Senior Care Corp. (LWSCF) Financials Nov 14,
Leisureworld Senior Care Corp. (LWSCF) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Leisureworld Senior Care Corp.
Fiscal year is January-December. All values CAD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 267.98M 213.61M 290.11M 319.28M 353.32M
Cost of Goods Sold (COGS) incl. D&A 263.23M 199.59M 282.27M 290.85M 318.86M
COGS excluding D&A 235.37M 180.17M 249.61M 262.95M 290.01M
Depreciation & Amortization Expense 27.86M 19.42M 32.67M 27.9M 28.85M
Depreciation 11.32M 8.39M 17.38M 18.95M 20.44M
Amortization of Intangibles 16.54M 11.03M 15.29M 8.95M 8.41M
Gross Income 4.75M 14.02M 7.84M 28.44M 34.46M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense - 9.17M - 13.99M 13.77M
Research & Development 0 0 0 0 0
Other SG&A - 9.17M - 13.99M 13.77M
Other Operating Expense 0 0 9.68M 0 0
Unusual Expense 0 31,000 0 5.93M 9.42M
EBIT after Unusual Expense 0 (31,000) 0 (5.93M) (9.42M)
Non Operating Income/Expense 361,000 0 0 0 (3.81M)
Non-Operating Interest Income 0 2.85M 3.23M 3.27M 3.85M
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 14.91M 13.25M 18.94M 18.62M 21.55M
Gross Interest Expense 14.91M 13.25M 18.94M 18.62M 21.55M
Interest Capitalized 0 0 0 0 0
Pretax Income (9.79M) (5.58M) (17.55M) (6.83M) (10.24M)
Income Tax (4.96M) (1.45M) (5.57M) 2.3M (857,000)
Income Tax - Current Domestic 1.06M 1.92M 1.19M 1.83M 613,000
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic (6.02M) (3.37M) (6.76M) 474,000 (1.47M)
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (4.83M) (4.13M) (11.98M) (9.13M) (9.38M)
Minority Interest Expense 0 0 0 0 0
Net Income (4.83M) (4.13M) (11.98M) (9.13M) (9.38M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (4.83M) (4.13M) (11.98M) (9.13M) (9.38M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (4.83M) (4.13M) (11.98M) (9.13M) (9.38M)
EPS (Basic) (0.24) (0.24) (0.52) (0.33) (0.31)
Basic Shares Outstanding 19.98M 17.39M 23.02M 27.35M 29.87M
EPS (Diluted) (0.24) (0.24) (0.52) (0.33) (0.31)
Diluted Shares Outstanding 19.98M 17.39M 23.02M 27.35M 29.87M
EBITDA 32.61M 24.27M 30.83M 42.34M 49.54M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Dollars and Sense: Affordable Cars in Raleigh Listen up, folks. These days, unless you're on the hunt for a fancy ride decked out with every bell and whistle, the idea of nabbing a car under ten grand almost sounds like a fairytale. But Auction Direct USA in Raleigh is making this dream a reality. That’s right, a whole fleet of used cars, all priced under $10,000, is...
Continue Reading
Revenue Surge but Margin Squeeze Out there in the land of HVAC, Lennox International (NYSE: LII) just dropped its third quarter earnings for 2026. Sure, they raked in a solid $1.6 billion—up a hearty 10%. But all that glitters ain't gold, and the company's operating income took a hit down to $312 million, shedding a cool five percent from last year. Challenges Weighing...
Continue Reading
The True Stories Behind Exorcisms In the complex landscape of media today, EWTN Studio's latest docuseries, In Jesus' Name, steps into the ring with tales that outstrip Hollywood's beloved fright flicks. Forget about the jumpscares and the special effects next to those greased-up eggs you're munching on. This series drills right to the bone of reality—a candid look at...
Continue Reading
Core Lab's Quarter in Review With the kind of resilience that makes a trader's hands shake ever so slightly less over a coffee, Core Laboratories Inc. heads into the fourth quarter of 2026. This isn't your typical Wall Street story, that's for sure. Watching a solid player like Core navigate the bumpy roads of today's volatile market reminds me of a...
Continue Reading
Record Financing Applications, But Not All is Rosy Diving headlong into this 1West data is like clutching at a double-edged sword. On one side, we've got record-breaking numbers—48,975 financing applications in Q3 alone. That’s a staggering 25% hike over last year. But before you pop the champagne, let's pivot to the other edge: dwindling financial health. With the...
Continue Reading
Stepping up to Spotlight Courage In a world that often seems to teeter on chaos, it's those unsung heroes—the first responders—who stand ready to turn panic into repose. October 28th saw Times Square in New York City transform into a beacon of appreciation as the First Responders Children's Foundation (FRCF) applauded nineteen fearless foes of danger. Picture that...
Continue Reading
Electricity Powerhouse Unleashes Ambitious Plan If you thought American Electric Power (NASDAQ:AEP) was just cruising along, think again. This week, they rolled out an eye-popping $100 billion plan to supercharge their infrastructure and meet soaring electricity demands. It’s like they’re building the future of power right in front of our eyes. Third-quarter earnings...
Continue Reading
Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...
Continue Reading
Cloopen Steps Away from Public Market Scene Here's a tale simmering on the corporate backburner: Cloopen Group Holding Limited, that cloud juggernaut over in China, has gone all private on us. The ink is drying on their merger with SummerX Holdings Limited, under the overarching umbrella of SpringX Holdings. So, now this communications outfit has slipped out of the public...
Continue Reading
Ever stood in a place where history feels so heavy you can almost touch it? That's Lazikou, a gorge in southern Gansu, where ninety years ago, young soldiers of China's Red Army faced a seemingly impassable barrier. Yet, they managed to climb, transform a military retreat into legend, and essentially shape the nation's path ahead. It's a feat that still sends ripples...
Continue Reading
Top 5 Most Recently Viewed Articles
Aeroderivative Gas Turbine Market Overview The Aeroderivative Gas Turbine market is experiencing remarkable growth, driven by increasing demands for efficient power generation and technological innovations. According to recent analysis, the market is projected to surge to an estimated value of USD 6.79 billion by 2034, marking a compound annual growth rate (CAGR) of...
Continue Reading
Chain.io Unveils New Snowflake Connectivity Chain.io has introduced an exciting connected application aimed at boosting the capabilities of supply chain teams. This innovative tool provides seamless access to supply chain data, paving the way for deeper insights and improved operational efficiency. Navigating the Complexities of Supply Chain Data Logistics and supply...
Continue Reading
Antalpha's Impressive Third Quarter Performance Antalpha Platform Holding Company (NASDAQ: ANTA) has recently unveiled promising financial results for the third quarter of this year. This period has proven pivotal as the company marked an extraordinary 62% growth in revenue over the previous year, highlighting the effectiveness of their Prime lending platform. Rapid...
Continue Reading
Understanding Class Actions and Your Rights If you've faced losses in your investments with Block, Inc. (XYZ), you may feel overwhelmed and uncertain about your next steps. Class action lawsuits can be an effective way for shareholders like you to seek justice and accountability from companies. The Gross Law Firm is reaching out to encourage affected investors to take...
Continue Reading
Acumen Pharmaceuticals Advances in Alzheimer’s Research Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a pioneering clinical-stage biopharmaceutical company, is at the forefront of developing a promising new treatment aimed at combating Alzheimer's disease. This innovative approach focuses on targeting soluble amyloid beta oligomers (A?Os), a significant physiological...
Continue Reading